FDA Approves Supplemental Application for Zyrtec Hives by Kenvue Brands
The FDA has approved a supplemental application for Zyrtec Hives, containing cetirizine hydrochloride.
Asset / Drug
Drug and asset intelligence for Allergy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.